AR128475A1 - POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY - Google Patents

POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY

Info

Publication number
AR128475A1
AR128475A1 ARP230100294A ARP230100294A AR128475A1 AR 128475 A1 AR128475 A1 AR 128475A1 AR P230100294 A ARP230100294 A AR P230100294A AR P230100294 A ARP230100294 A AR P230100294A AR 128475 A1 AR128475 A1 AR 128475A1
Authority
AR
Argentina
Prior art keywords
polypeptide
tslp
binding
fusion protein
expression vector
Prior art date
Application number
ARP230100294A
Other languages
Spanish (es)
Inventor
Anna Edvardsson
Lindvi Gudmundsdotter
Siavash Kijani
Susanne Klint
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of AR128475A1 publication Critical patent/AR128475A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con una clase de polipéptidos obtenidos por ingeniería que tiene una afinidad de unión a la linfoproteína estromal tímica (TSLP) y proporciona un polipéptido de unión a TSLP que comprende la secuencia EAVX⁴ALX⁷EIWX¹¹LPNLX¹⁶X¹⁷X¹⁸QX²⁰X²¹AFIX²⁵X²⁶LRD o una secuencia que tiene al menos 93% de identidad con la misma. La presente descripción también ser relaciona con el uso de dicho polipéptido de unión a TSLP como un agente terapéutico, de pronóstico y/o de diagnóstico. Reivindicación 62: Polinucleótido que codifica un polipéptido de unión a TSLP o proteína de fusión de acuerdo con cualquier reivindicación precedente. Reivindicación 63: Vector de expresión que codifica un polinucleótido de acuerdo con la reivindicación 62. Reivindicación 64: Célula huésped que comprende un vector de expresión de acuerdo con la reivindicación 63. Reivindicación 65: Método de producción de un polipéptido, proteína de fusión o conjugado de acuerdo con una cualquiera de las reivindicaciones 1 - 60 que comprende cultivar una célula huésped de acuerdo con la reivindicación 64 bajo condiciones que permiten la expresión de dicho polipéptido a partir de dicho vector de expresión; y aislar dicho polipéptido. Reivindicación 66: Composición que comprende un polipéptido, proteína de fusión o conjugado de unión a TSLP de acuerdo con una cualquiera de las reivindicaciones 1 - 61 y al menos un excipiente o portador farmacéuticamente aceptable.The present disclosure relates to a class of engineered polypeptides having a binding affinity to thymic stromal lymphoprotein (TSLP) and provides a TSLP-binding polypeptide comprising the sequence EAVX⁴ALX⁷EIWX¹¹LPNLX¹⁶X¹⁷X¹⁸QX²⁰X²¹AFIX²⁵X²⁶LRD or a sequence having at least 93% of identity with it. The present description also relates to the use of said TSLP-binding polypeptide as a therapeutic, prognostic and/or diagnostic agent. Claim 62: Polynucleotide encoding a TSLP-binding polypeptide or fusion protein according to any preceding claim. Claim 63: Expression vector encoding a polynucleotide according to claim 62. Claim 64: Host cell comprising an expression vector according to claim 63. Claim 65: Method of producing a polypeptide, fusion protein or conjugate according to any one of claims 1-60 comprising culturing a host cell according to claim 64 under conditions that allow expression of said polypeptide from said expression vector; and isolating said polypeptide. Claim 66: Composition comprising a polypeptide, fusion protein or TSLP binding conjugate according to any one of claims 1-61 and at least one pharmaceutically acceptable excipient or carrier.

ARP230100294A 2022-02-08 2023-02-08 POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY AR128475A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22155646 2022-02-08

Publications (1)

Publication Number Publication Date
AR128475A1 true AR128475A1 (en) 2024-05-15

Family

ID=80682629

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100294A AR128475A1 (en) 2022-02-08 2023-02-08 POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY

Country Status (7)

Country Link
KR (1) KR20240139058A (en)
CN (1) CN118632866A (en)
AR (1) AR128475A1 (en)
AU (1) AU2023218534A1 (en)
IL (1) IL314458A (en)
MX (1) MX2024009732A (en)
WO (1) WO2023152144A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546261A3 (en) 2007-07-31 2013-08-14 Affibody AB New compositions, methods and use
WO2009077175A1 (en) 2007-12-19 2009-06-25 Affibody Ab Polypeptide derived from protein a and able to bind pdgf
CN110437321A (en) 2010-07-09 2019-11-12 阿菲博迪公司 Polypeptide
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
CN106488930B (en) 2014-06-13 2021-11-02 阿菲博迪公司 Novel polypeptides
PT3245224T (en) * 2015-01-12 2020-10-08 Affibody Ab Il-17a-binding polypeptides
CA3001264A1 (en) 2015-10-30 2017-05-04 Affibody Ab Pd-l1 binding polypeptide
US20220389066A1 (en) * 2019-11-05 2022-12-08 Affibody Ab Polypeptides

Also Published As

Publication number Publication date
IL314458A (en) 2024-09-01
KR20240139058A (en) 2024-09-20
AU2023218534A1 (en) 2024-07-11
WO2023152144A1 (en) 2023-08-17
MX2024009732A (en) 2024-08-19
CN118632866A (en) 2024-09-10

Similar Documents

Publication Publication Date Title
EP4272765A3 (en) Adeno-associated virus (aav) clade f vector and uses therefor
Baberg et al. Secretome analysis of human bone marrow derived mesenchymal stromal cells
CA2283462A1 (en) Vectors having enhanced expression and methods of making and uses thereof
AR055191A1 (en) GENERATION AND CHARACTERIZATION OF THERAPEUTIC ANTIBODIES DERIVED FROM HUCAL- GOLD FULLY HUMAN SPECIFIC FOR THE HUMAN CD38
JP2020502262A5 (en)
MX2022007120A (en) Recombinant peptide-mhc complex binding proteins and their generation and use.
BR112022016657A2 (en) BCMA CAR-T CELLS WITH IMPROVED ACTIVITIES
CO6270336A2 (en) PEPTICIDE COMPOSITIONS THAT INCLUDE ONE OR MORE POLYPTIDES
BR9813416A (en) Compositions and methods of recombinant nodaviruses
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
ATE449790T1 (en) RECOMBINANT GELATIN PARTICLES FOR CELL ADHESION
DK200601181A (en) fish vaccine
DE60131450D1 (en) HEFEEXPRESSION VECTOR AND METHOD FOR PRODUCING A RECOMBINANT PROTEIN BY EXPRESSION IN A HEFING CELL
MX2022014938A (en) Proteins comprising cd3 antigen binding domains and uses thereof.
BR112023003526A2 (en) IMMUNOGENIC CORONAVIRUS FUSION PROTEINS AND RELATED METHODS
WO2021116470A3 (en) Recombinant peptide-mhc complex binding proteins and their generation and use
BRPI0410562B8 (en) carrier protein and its production method in a plant, isolated nucleic acid, expression vector and host cell
AR083586A1 (en) FACTOR PEPTIDES VIII (FVIII) FOR IMMUNE TOLERANCE INDUCTION AND FOR IMMUNODIAGNOSIS
CL2023001434A1 (en) il-2 mutein; fusion protein; nucleic acid; vector; host cell; methods; use
WO2021252406A3 (en) Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof
BR112021026326A2 (en) Engineered sucrose phosphorylase, composition, polynucleotide sequence, expression vector, host cell, and method for producing an engineered sucrose phosphorylase
WO2021239838A3 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
AR128475A1 (en) POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY
ATE327251T1 (en) METHOD OF REDUCING THE IMMUNOGENICITY OF STAPHYLOKINASE BY REMOVAL OF T-CELL EPITOPES
Antonyshyn et al. Vascular tissue engineering from human adipose tissue: fundamental phenotype of its resident microvascular endothelial cells and stromal/stem cells